

Treating Patients With Traumatic Chondral Lesions With Autologous Bone Marrow Cells Derived Engineered Tissues - Engineered Osteochondral Tissue

NCT06400862

Status	RECRUITING
Phase	Phase 1
Sponsor	Chinese University of Hong Kong
Enrollment	9 participants

Key Eligibility Criteria

Inclusion (5)

- Age: Subjects who are in the age range of 18-60 years
- Location: Single symptomatic cartilage defect on medial or lateral femoral condyle
- Size & Containment: Contained single focal cartilage lesion of size ~1-4 cm square
- Grading: Cartilage damage ICRS/Outerbridge grade III/IV reaching subchondral bone (As diagnosed by MRI)
- Conservative treatments failed (for > 4 months)

Exclusion (30)

- Disease Factor---
- Previous cartilage repair surgery (OATS or ACI/MACI) in the index knee
- Previous injectational treatments such as HA/PRP/stem cell in the index knee within 3 months before informed consent
- Presence of a clinically relevant patellofemoral cartilage lesion in the index knee (patella/trochlea/both)
- Inflammatory joint disease (specific or non-specific arthritis)
- ... and 25 more (see full listing online)

Locations (2 total)

Queen Elizabeth Hospital, Jordan, Hong Kong
Prince of Wales Hospital, Shatin, Hong Kong